Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

RVX-297

Copy Product Info
🥰Excellent
Catalog No. T28628Cas No. 1044871-04-6
Alias RVX297

RVX-297 is a BD2 selective inhibitor of BET bromodomains. RVX-297 preferentially binds to the BD2 domains of the BET bromodomain and Extra Terminal (BET) family of protein.

RVX-297

RVX-297

Copy Product Info
🥰Excellent
Purity: 99.62%
Catalog No. T28628Alias RVX297Cas No. 1044871-04-6
RVX-297 is a BD2 selective inhibitor of BET bromodomains. RVX-297 preferentially binds to the BD2 domains of the BET bromodomain and Extra Terminal (BET) family of protein.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
5 mg$41In StockIn Stock
10 mg$68In StockIn Stock
25 mg$138In StockIn Stock
50 mg$222In StockIn Stock
100 mg$358In StockIn Stock
1 mL x 10 mM (in DMSO)$46In StockIn Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.62%
Appearance:Solid
Color:White
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
RVX-297 is a BD2 selective inhibitor of BET bromodomains. RVX-297 preferentially binds to the BD2 domains of the BET bromodomain and Extra Terminal (BET) family of protein.
Targets&IC50
BRD4 BD1:1.16 μM, BRD2 BD1:3.76 μM, BRD4 BD2:0.02 μM, BRD3 BD2:0.05 μM, BRD3 BD1:2.34 μM, BRDT BD1:2.69 μM, BRD2 BD2:0.08 μM
In vitro
RVX-297 suppressed IL-6 gene induction in human U937 macrophages, mouse primary B cells isolated from the spleen, mouse BMDMs, and THP-1 monocytes in a dose-dependent manner[2].
In vivo
In the rCIA model, RVX-297 treatment had a substantial impact on cytokine gene expression; expressions of IL-1β, RANKL, MMP3, and MMP13 were all significantly decreased in the ankle joints of arthritic rats after RVX-297 treatment at 75 mg/kg BID versus vehicle-treated arthritic controls[2].
SynonymsRVX297
Chemical Properties
Molecular Weight423.5
FormulaC24H29N3O4
Cas No.1044871-04-6
SmilesCOc1cc(OC)c2c(c1)nc([nH]c2=O)-c1cc(C)c(OCCN2CCCC2)c(C)c1
Relative Density.1.25 g/cm3 (Predicted)
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 40 mg/mL (94.45 mM), Sonication is recommended.
In Vivo Formulation
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.72 mM), Sonication is recommended.
Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.3613 mL11.8064 mL23.6128 mL118.0638 mL
5 mM0.4723 mL2.3613 mL4.7226 mL23.6128 mL
10 mM0.2361 mL1.1806 mL2.3613 mL11.8064 mL
20 mM0.1181 mL0.5903 mL1.1806 mL5.9032 mL
50 mM0.0472 mL0.2361 mL0.4723 mL2.3613 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy RVX-297 | purchase RVX-297 | RVX-297 cost | order RVX-297 | RVX-297 chemical structure | RVX-297 in vivo | RVX-297 in vitro | RVX-297 formula | RVX-297 molecular weight